US drug market will reach US$334 billion in 2014

Business News, November 9th Although the US drug market will slow down in the next five years, BMI predicts that its compound annual growth rate will still reach 1.76%, which is mainly affected by many factors, such as expiration and ongoing The medical reforms, these factors have played a role in promoting the US drug market. By 2014, the U.S. drug market will reach US$334 billion, and it will remain the world’s number one position. In 2009, the US drug market was approximately US$306 billion. .

Drug safety issues are still the focus of FDA's work. During this period, the regulatory environment in the United States remains a model for all countries in the world to learn. The FDA recently opened a drug safety evaluation website to publish online the results of the safety evaluation of recently approved drugs or vaccines. In addition, the FDA is still in Drugs. Com has established a Memorandum of Understanding (MOU) for collaborative public education programs and hopes to strengthen the application of consumer health information.

Last quarter, the US drug market was extremely active. Johnsons recalled 21 drugs, including children and adults Tylenol and several other OTC drugs such as Benadryl and Motrin. Since Johnson & Johnson is not prepared to introduce these products by the end of this year, the Swiss company Novartis decided to fill the gap in the children's oral liquid medicine. Triaminic, which is used to reduce fever and relieve pain, will have a market of 1.5 million US dollars.

The development of the drug market is mainly affected by factors such as the economic environment and health care reform. It is estimated that the US’s GDP will increase by 2.8% this year and increase by 1.8% next year. Due to the lack of economic growth, the GDP in the fourth quarter and the first two quarters of this year will increase by 5.0%, 3.7%, and 2.4%, respectively, and will continue to decline. This has led to a decline in consumer growth, including the purchasing power of drugs. In particular, there have been reports that some patients have spent too much time purchasing drugs they need. Medical institutions of insured persons in the United States are also declining. Insurance companies, laboratory testing companies, hospitals, and doctors reported that patient visits, drug prescriptions, and purchases have declined year-on-year in the second quarter of this year.